Although this study focused on NAFLD, it demonstrates the potential of targeting the lncRNA MALAT1 in the treatment of liver disease, which also provides a potential therapeutic strategy for future applications in ALD. Here, MALAT1 is linked to metabolic dysfunction-associated steatotic liver disease.